Fouling of virus filtration membranes by monoclonal antibody feeds with low aggregate content

Author:

Kaufman Yair1ORCID,Hunt KC1,Hale Gabriel1,McClure Matthew2,Latulippe David2,Sivan Madhavi1,Wilson Jack1,Dorin Rachel1,Agroskin Yury1,Siwak Marty1,Gerion Daniele1

Affiliation:

1. TeraPore Technologies South San Francisco California USA

2. Department of Chemical Engineering McMaster University Hamilton Ontario Canada

Abstract

AbstractMembrane fouling by monoclonal antibodies (mAbs) is one of the main challenges in virus‐filtration processes. Previous publications attributed membrane fouling to the presence of mAb aggregates in the solution, which block the membrane pores. This fouling mechanism can be solved by a prefilter; however, it was shown that there are mAbs that severely foul the membranes (reduce permeability by 90% and more) even after prefiltering the aggregates, while other mAbs foul the membrane weakly (reduce permeability by ~10% and less). Unfortunately, the differences between the fouling‐ and the nonfouling mAbs have never been convincingly explained. To get a deeper insight on these differences, we measured the fouling of chemically modified Isoprene‐Styrene‐4‐vinylpyridine (ISV) membranes (TeraPore Technologies) by 8 mAbs exhibiting different hydrophobicity and charge. The results show that mAb solutions with low concentration of aggregates foul ISV membranes via an adsorptive mechanism, and the adsorption is driven mainly by hydrophobic forces between the mAb and the membrane. The charge of the mAbs plays a secondary role in fouling. We want to emphasize that the conclusions pertain to ISV membranes; the insights presented in this paper can potentially be used to engineer new surface chemistries to mitigate fouling of other virus‐filtration and/or ultrafiltration membranes.

Publisher

Wiley

Subject

Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Reference31 articles.

1. Bak H.(2022).Precision medicine for cancer treatment leveraging industrialized robust and simple bispecific antibody platform: Learnings from a 10‐year journey presented at the recovery conference July 11.

2. Investigation of fouling mechanisms of virus filters during the filtration of protein solutions using a high throughput filtration screening device

3. Blankenship K.(2019). The top 20 drugs by 2018 U.S. Sales.https://www.fiercepharma.com/special-report/top-20-drugs-by-2018-u-s-sales

4. Blankenship K.(2020). The top 20 drugs by 2018 U.S. Sales.https://www.fiercepharma.com/special-report/top-20-drugs-by-2018-u-s-sales

5. Increasing the capacity of parvovirus-retentive membranes: performance of the Viresolve™ Prefilter

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3